Cargando…

Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study*

BACKGROUND: Pityriasis versicolor is a fungal infection caused by Malassezia spp. that has frequent relapses. OBJECTIVES: The main objective of this research was to perform phase I and II clinical studies, using formulations containing essential oil of Cymbopogon citratus in patients with pityriasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmo, Egberto Santos, Pereira, Fillipe de Oliveira, Cavalcante, Neuza Maria, Gayoso, Carla Wanderley, Lima, Edeltrudes de Oliveira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754369/
https://www.ncbi.nlm.nih.gov/pubmed/23793205
http://dx.doi.org/10.1590/abd1806-4841.20131800
_version_ 1782281895855259648
author Carmo, Egberto Santos
Pereira, Fillipe de Oliveira
Cavalcante, Neuza Maria
Gayoso, Carla Wanderley
Lima, Edeltrudes de Oliveira
author_facet Carmo, Egberto Santos
Pereira, Fillipe de Oliveira
Cavalcante, Neuza Maria
Gayoso, Carla Wanderley
Lima, Edeltrudes de Oliveira
author_sort Carmo, Egberto Santos
collection PubMed
description BACKGROUND: Pityriasis versicolor is a fungal infection caused by Malassezia spp. that has frequent relapses. OBJECTIVES: The main objective of this research was to perform phase I and II clinical studies, using formulations containing essential oil of Cymbopogon citratus in patients with pityriasis versicolor. METHODS: Phase I study included twenty volunteers to ascertain the safety of the formulations. In phase II, 47 volunteers randomly received essential oil formulations at 1.25 μL/mL concentration, for forty days. The shampoo should be applied three times a week and the cream twice a day. A control group in phase II, consisting of 29 volunteers, received the same formulations but with 2% ketoconazole as the active ingredient. RESULTS: No significant adverse events were observed in volunteers during Phase I. In Phase II, 30 (63.83%) volunteers using essential oil and 18 (62.07%) using ketoconazole remained until the end of the study. We observed a predominance of lesions in disseminated form, with M. sympodialis detected as the predominant agent identified in cultures. After 40 days of treatment, the rate of mycological cure was 60% (p <0.05) for the group treated with essential oil of C. citratus and over 80% (p <0.05) for the group treated with ketoconazole formulations. CONCLUSIONS: Notwithstanding the safety and antifungal effects observed in this study after application of formulations containing the essential oil of C. citratus, further studies with larger populations should be performed to confirm the actual potential of these formulations in the treatment of patients with Pityriasis versicolor.
format Online
Article
Text
id pubmed-3754369
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Sociedade Brasileira de Dermatologia
record_format MEDLINE/PubMed
spelling pubmed-37543692013-09-16 Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study* Carmo, Egberto Santos Pereira, Fillipe de Oliveira Cavalcante, Neuza Maria Gayoso, Carla Wanderley Lima, Edeltrudes de Oliveira An Bras Dermatol Investigation BACKGROUND: Pityriasis versicolor is a fungal infection caused by Malassezia spp. that has frequent relapses. OBJECTIVES: The main objective of this research was to perform phase I and II clinical studies, using formulations containing essential oil of Cymbopogon citratus in patients with pityriasis versicolor. METHODS: Phase I study included twenty volunteers to ascertain the safety of the formulations. In phase II, 47 volunteers randomly received essential oil formulations at 1.25 μL/mL concentration, for forty days. The shampoo should be applied three times a week and the cream twice a day. A control group in phase II, consisting of 29 volunteers, received the same formulations but with 2% ketoconazole as the active ingredient. RESULTS: No significant adverse events were observed in volunteers during Phase I. In Phase II, 30 (63.83%) volunteers using essential oil and 18 (62.07%) using ketoconazole remained until the end of the study. We observed a predominance of lesions in disseminated form, with M. sympodialis detected as the predominant agent identified in cultures. After 40 days of treatment, the rate of mycological cure was 60% (p <0.05) for the group treated with essential oil of C. citratus and over 80% (p <0.05) for the group treated with ketoconazole formulations. CONCLUSIONS: Notwithstanding the safety and antifungal effects observed in this study after application of formulations containing the essential oil of C. citratus, further studies with larger populations should be performed to confirm the actual potential of these formulations in the treatment of patients with Pityriasis versicolor. Sociedade Brasileira de Dermatologia 2013 /pmc/articles/PMC3754369/ /pubmed/23793205 http://dx.doi.org/10.1590/abd1806-4841.20131800 Text en ©2013 by Anais Brasileiros de Dermatologia http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Investigation
Carmo, Egberto Santos
Pereira, Fillipe de Oliveira
Cavalcante, Neuza Maria
Gayoso, Carla Wanderley
Lima, Edeltrudes de Oliveira
Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study*
title Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study*
title_full Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study*
title_fullStr Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study*
title_full_unstemmed Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study*
title_short Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study*
title_sort treatment of pityriasis versicolor with topical application of essential oil of cymbopogon citratus (dc) stapf - therapeutic pilot study*
topic Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754369/
https://www.ncbi.nlm.nih.gov/pubmed/23793205
http://dx.doi.org/10.1590/abd1806-4841.20131800
work_keys_str_mv AT carmoegbertosantos treatmentofpityriasisversicolorwithtopicalapplicationofessentialoilofcymbopogoncitratusdcstapftherapeuticpilotstudy
AT pereirafillipedeoliveira treatmentofpityriasisversicolorwithtopicalapplicationofessentialoilofcymbopogoncitratusdcstapftherapeuticpilotstudy
AT cavalcanteneuzamaria treatmentofpityriasisversicolorwithtopicalapplicationofessentialoilofcymbopogoncitratusdcstapftherapeuticpilotstudy
AT gayosocarlawanderley treatmentofpityriasisversicolorwithtopicalapplicationofessentialoilofcymbopogoncitratusdcstapftherapeuticpilotstudy
AT limaedeltrudesdeoliveira treatmentofpityriasisversicolorwithtopicalapplicationofessentialoilofcymbopogoncitratusdcstapftherapeuticpilotstudy